Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.76 |
| ▸ | JAK2 | O60674 | 4/20 | 0.76 |
| ▸ | JAK1 | P23458 | 3/20 | 0.76 |
| ▸ | STAT3 | P40763 | 1/20 | 0.76 |
| ▸ | STAT1 | P42224 | 1/20 | 0.76 |
| ▸ | JAK3 | P52333 | 1/20 | 0.76 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30924053 | 0.92 | TYK2 (0.75) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL30062445 | 0.87 | TYK2 (0.75) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL20520348 | 0.87 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29424395 | 0.87 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29375597 | 0.86 | TYK2 (0.98) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29619500 | 0.86 | TYK2 (0.98) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL30278579 | 0.86 | TYK2 (0.98) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL30065932 | 0.85 | TYK2 (0.78) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29672334 | 0.83 | TYK2 (0.94) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29672326 | 0.83 | TYK2 (0.92) | TYK2JAK2JAK1STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115448910-B | Pyridazine derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-04-19 | — | — | CN | disclosed |